



Post Authorisation Assessments

For details of post authorisation assessments prior to 1st January 2021,
please refer to the [EMA](#) website.

Bravecto 500 mg Spot-on Solution for Large Cats (>6.25 – 12.5 kg) Vm 01708/5025

10 December 2024	Editorial changes to part 2 of the dossier if inclusion in an upcoming procedure concerning part 2 is not possible.
24 January 2024	Alignment of product information with the national SPC/QRD template.
13 June 2023	Unlimited renewal
21 June 2022	Change in the name of a manufacturer of the active substance.
08 December 2021	Changes in the SPC, Labelling or Package Leaflet intended to implement the outcome of a procedure concerning a periodic safety update report (PSUR.)
30 July 2021	Addition of a pair of gloves per pipette in the carton box.
06 May 2021	Addition of a primary packaging site. Addition of a secondary packaging site. Change in the manufacturing process of the finished product. Change in the manufacturing process of the finished product. Addition of a bulk manufacturing site.
04 March 2021	Deletion of site where batch control takes place